XML 28 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (5,462,047) $ (990,980)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of deferred financing fees 129 1,191
Amortization of debt discount 396 3,738
Share-based compensation expense, including stock issued to consultants and advisors 1,864,913 8,483
Change in fair value of derivative liability 26,500 79,500
Changes in assets and liabilities:    
Grant receivable 735,075 (735,075)
Prepaid expenses and other current assets (34,097) 5,101
Accounts payable (695,660) 969,091
Accrued expenses (406,032) 182,409
Net cash used in operating activities (3,970,823) (476,542)
Cash flows from financing activities:    
Proceeds from initial public offering of common stock, net of offering costs 12,034,406  
Proceeds from issuance of convertible promissory notes   530,000
Proceeds from exercise of stock options 9,217  
Payment of deferred offering costs   (78,611)
Payment of deferred financing fees   (8,301)
Net cash provided by financing activities 12,043,623 443,088
Net increase (decrease) in cash 8,072,800 (33,454)
Cash and cash equivalents, beginning of year 1,858 35,312
Cash and cash equivalents, end of year 8,074,658 1,858
Supplemental disclosure of cash flow information    
Deferred offering costs in accounts payable and accrued expenses   290,984
Deferred financing fees in accounts payable and accrued expenses   $ 321
Conversion of redeemable convertible preferred stock to common stock 7,076,952  
Conversion of convertible promissory notes, including embedded derivative, to common stock $ 672,524